Lapelga 6 mg

Lapelga 6 mg is a subcutaneous solution containing pegfilgrastim, used to support white blood cell production during chemotherapy. This medication helps reduce infection risk in cancer patients.

Lapelga 6 mg is primarily used to stimulate the production of white blood cells in individuals undergoing chemotherapy. This helps to mitigate the risk of infections, which can be a common side effect of cancer treatment. Pegfilgrastim, the active ingredient, works by supporting the body's natural defenses during periods of immune suppression.

Common effects of Lapelga 6 mg may include bone pain, fatigue, and mild allergic reactions at the injection site. These effects are generally temporary and should be discussed with a healthcare provider if they persist or worsen. Individual responses to the medication can vary.

Lapelga 6 mg should be handled with care, ensuring proper storage and administration as directed. It is important to follow the prescribed guidelines for subcutaneous injection to minimize the risk of complications. Always consult a healthcare professional for personalized advice.

Lapelga 6 mg may interact with other medications, particularly those that affect the immune system. It is advisable to inform your healthcare provider about all current medications, including over-the-counter drugs and supplements, to avoid potential interactions.